Appendix:

Table 5: Systemic treatments given before and after pazopanib

|  | **Patients received previous line treatment agents (N=46)** | **Patients received further line treatment agents**  **(N=38)** |
| --- | --- | --- |
|  | **Yes**  **N (%)** | **Yes**  **N (%)** |
| **Paclitaxel** | 25 (54.3) | 7 (18.4) |
| **Doxorubicin** | 20 (43.5) | 2 (5.3) |
| **Docetaxel** | 11 (23.9) | 2 (5.3) |
| **Gemcitabine** | 11 (23.9) | 8 (21.1) |
| **Ifosfamide** | 8 (17.4) | 1 (2.6) |
| **Epirubicin** | 7 (15.2) | 0 |
| **Dacarbazine** | 3 (6.5) | 1 (2.6) |
| **Brentuximab** | 2 (4.3) | 0 |
| **Trabectedin** | 2 (4.3) | 1 (2.6) |
| **Alpha interferon** | 1 (2.2) | 0 |
| **Carboplatin** | 1 (2.2) | 0 |
| **Cyclophosphamide** | 1 (2.2) | 2 (5.3) |
| **Lenalidomide** | 1 (2.2) | 0 |
| **Melphalan** | 1 (2.2) | 0 |
| **Vinorelbine** | 1 (2.2) | 0 |
| **Thalidomide** | 1 (2.2) | 0 |
| **Cisplatin** | 0 | 1 (2.6) |
| **Etoposide** | 0 | 1 (2.6) |
| **Pembrolizumab** | 0 | 1 (2.6) |
| **Trofosfamide** | 0 | 1 (2.6) |